The Effects of Co-payments within Drug Reimbursement Programs
Prescription drug expenditures are one of the fastest rising components of provincial health care spending. One of the primary responses of provincial governments to rising drug expenditures has been to introduce or increase beneficiary co-payment requirements. This paper examines the evidence regarding the effects of co-payments on drug program expenditures, the appropriateness of drug utilization, and the efficiency with which prescription drug markets operate. Although drug co-payments can reduce drug program expenditures, they can only do so by compromising other program goals. Alternative policies are then discussed that may help contain costs without compromising, and in some instances even improving, drug therapy.
If you experience problems downloading a file, check if you have the proper application to view it first. In case of further problems read the IDEAS help page. Note that these files are not on the IDEAS site. Please be patient as the files may be large.
As the access to this document is restricted, you may want to look for a different version under "Related research" (further below) or search for a different version of it.
Volume (Year): 17 (1991)
Issue (Month): 4 (December)
|Contact details of provider:|| Postal: University of Toronto Press Journals Division 5201 Dufferin Street Toronto, Ontario, Canada M3H 5T8|
Web page: http://economics.ca/cpp/
|Order Information:|| Web: http://www.utpjournals.com/cpp/ Email: |
When requesting a correction, please mention this item's handle: RePEc:cpp:issued:v:17:y:1991:i:4:p:473-489. See general information about how to correct material in RePEc.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Prof. Werner Antweiler)
If references are entirely missing, you can add them using this form.